3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
14
Anemia, Refractory, with Excess of Blasts
13
Myelodysplastic Syndromes
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myelomonocytic, Chronic
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia
7
Lymphoma, Non-Hodgkin
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hodgkin Disease
6
Myeloproliferative Disorders
5
Multiple Myeloma
5
Blast Crisis
5
Lymphoma
4
Leukemia, Myeloid, Chronic-Phase
4
Anemia, Refractory
4
Primary Myelofibrosis
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myeloid, Accelerated Phase
3
Dendritic Cell Sarcoma, Interdigitating
3
Congenital Abnormalities
3
Burkitt Lymphoma
3
Anemia, Aplastic
3
Thrombocytopenia
2
Neutropenia
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Follicular
2
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
Classical hematology
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled